PT | EN Home > RESOLVE TEAMS - First Edition
RESOLVE TEAMS - First Edition
Adapttech

Members: Mario Espinoza, Frederico Carpinteiro, Sofia Assis, Sara Moura

The adapttech project comprises a smart prosthetic-fitting solution specially developed for prosthetists that is able to locate hard-to-identify problems on the stump-socket interface. For additional information please visit the start-up website:  http://www.adapttech.eu/.

 

AntiBioCoat

Members: Rita Mota, Fabíola Costa, Cristina Martins, Paula Tamagnini 

Anti-adhesive Biopolymer Coating (AntiBioCoat) is a project focused on developing an anti-adhesive coating based on a polymer naturally produced by a marine bacterium. This biopolymer-based coating can be applied to any existing catheter (e.g. urinary, central venous) to prevent bacterial adhesion and the subsequent host bacterial infection resulting in a cost effective way to reduce one of the most common health care acquired infections.

ARNanoFilm

Members: José das Neves, Bruno Sarmento

This technology comprises the incorporation of antiretroviral drug-loaded nanoparticles into thin polymeric films. These systems are intended to be placed in the vagina in order to prevent male-to-female sexual transmission of HIV. It is expected that drug-loaded nanoparticles-in-films may provide enhanced safety and efficacy as compared to more conventional formulations previously tested in clinical trials. The major goal of the ARNanoFilm project is to empower women worldwide with a novel option for protection against HIV/AIDS.

BestHealth

Members: Sónia Ferreira, Nelson Oliveira

BestHealth is focused on developing a new generation of medical adhesives that protect the skin under continuous or critical usage, to be applied in areas as ostomy, disposable medical sensors, hot and cold therapy, wound dressing, plaster and other.

RUBYnanomed

Members: Lorena Dieguez, Silvina Samy

Metastatic disease is directly responsible for most of cancer-related deaths worldwide. Circulating tumor cells (CTCs) shedding from the primary tumor have the ability to invade other organs, causing metastasis. Their study allows continuous and real-time monitoring of metastatic cancer progression based on a low invasive sampling in cancer patients, constituting the so-called liquid biopsy.
RUBYnanomed enables liquid biopsy for metastatic cancer at the point-of-care. It uses a proprietary cell microfluidic capture tool that can be used for early cancer metastasis detection, better prognosis and personalized treatment.

Glucodii

Members: Salomé Pinho, Ana Dias, Márcia Pereira

Inflammatory Bowel Disease (IBD) is a chronic, relapsing and life-long immune-mediated disorder of the gastrointestinal tract that affects over 2.5 million residents in Europe and has an increasing incidence worldwide. The current therapeutic strategies for IBD are limited by reduced effectiveness (failure in therapy response) and/or toxicity. The main goal of GLUCODII team is to provide an additional therapeutic strategy to IBD patients, and thus improving patients’ quality of life. We have been generating pre-clinical data that support the efficacy of a new agent in IBD which warrants the validation in a human clinical trial.

HECOLCAP

Members: Susana Sousa, Fernando Jorge Monteiro

HECOLCAP is based on a Single-step osteomyelitis treatment which, after debridement, implants a novel construct constituted by bone defect geometry adjusting scaffolds based on novel biomaterial and an antibiotic. The antibiotic is released in therapeutic dosages over an adequate period. After eliminating the infection, the construct is able to promote the recruitment, binding and proliferation of bone cells, resulting in increased new bone formation rate and reducing patient recovery time. This technology shows a differentiating character in a diverse range of applications, namely dental, veterinary surgery, and oncology.

RESOLVE TEAMS - Second Edition
ProREGEN

Members: Mónica Sousa, Ana Rita Costa

Spinal cord injury (SCI) affects over 200.000 patients worldwide every year. Despite considerable progress in the medical, surgical, and rehabilitation of SCI patients, there are no effective treatments improving neurologic outcome. Thus, it is essential to identify translatable therapies favouring axon regrowth and spinal cord repair. Our goal is to evaluate the in vivo regenerative potential of constitutively active Profilin-1 (Pfn1) after lesion. Our data demonstrates that in vitro delivery of Pfn1 is a robust enhancer of axon growth with an unprecedented effect in the field. If successful, this therapy could be applicable to other conditions where axon regeneration is needed.

SurgeonMate

Members: Nuno Muralha, Rúben Marques

SurgeonMate Vision is a device that creates highly specialized multimedia records in operating rooms. It is a pair of protection glasses equipped with a Camera integrated in the frame  that is motorized to guarantee the SURGEONS’ POINT OF VIEW is correctly captured. Computer vision algorithms protect the privacy of everyone on film. Managing multimedia requires many tools, but SurgeonMate Library combines in one platform everything that is needed to treat multimedia content with a customized and safe library.

GlycoTarget

Members: Celso Reis, Diana Campos, Filipe Pinto

Gastric cancer (GC) is an aggressive disease that continues to have a daunting impact on global health. Treatment of advanced GC has seen little progress and median overall survival in this group remains poor. Therefore, there is a need for novel diagnostic and therapeutic targets. GlycoTarget aims to develop new antibodies to tumor specific epitopes. Monoclonal antibodies targeting abnormal, cancer-specific epitopes on cell surface glycoproteins will provide innovative diagnostic and therapy strategies for GC patients.

Symbiosis

Members: Lúcia Brandão, Helena Sá, Margarida Saraiva

The re-emergence of tuberculosis (TB) associated with modern epidemics and immune therapies threatens the progress made in controlling this disease. Tailor-made interventions are needed to tackle the many faces of TB, in particular the transition from latency to infectious, active disease. Developing molecular-based point-of-care tests to stratify the estimated 2 billion latently infected individuals for their risk of reactivation would allow focusing treatment on those at higher risk, considerably reducing the number of people undergoing preventive antibiotherapy and the toxic side effects associated with it. Based on previous research from the involved teams, Symbiosis addresses a rapid diagnostic test for risk stratification of latent TB.

 

Facegram

Members: Paulo Aguiar, Ana Gerós

Facegram is proposed as a new standard and a universal tool for detailed analysis of facial movements in the context of therapy, surgery and rehabilitation of the face. It is presented as a new strategy to compile and visualize morphometric data, including a set of distilled measurements with clinical usefulness that can be easily interpreted by a physician. Just as a cardiogram or an audiogram are crucial medical tools to assess heart or hearing disorders, the Facegram compiles precise and objective quantitative measures regarding facial static and dynamical properties.

OncoAdvanc+

Members: Maria Alice Carvalho, Marta Oliveira, Sérgia Velho

OncoAdvanC+ focus on the pre-clinical evaluation of new chemical compounds for colorectal cancer treatment. Standard anti-cancer therapies are limited as they do not target the origin of the problem- the mutant molecule. As so, cancer cells become resistant, leading to disease progression. A promising lead compound has been identified which targets two important oncogenes for cancer development and progression that currently lack efficient inhibitors, thus offering unique clinical value for personalized medicine.

Pathowatch.med

Members: Manuela Oliveira

Within the hospital environment, circulating pathogenic agents (e.g. bacteria, fungi, virus) maytrigger hospital-acquired infections (HAI). Over the last decade, this issue has continuously evolved to a current state of significant concern.

The solution proposed by PathoWatch.med consists of an innovative method for monitoring foci of infection by pathogens as an instrument to control the rate of HAIs. PathoWatch.med contemplates the sampling (swabbing) of hospital surfaces, followed by the application of cutting-edge technology for the assessment of the main bacteria associated with HAIs, according to DGS.

SkinLesionRS

Members: Nuno Felicio, Luis Rosado, Maria Vasconcelos

”Skin cancer corresponds to 1/3 of all cancers and malignant melanoma is responsible for most skin cancer deaths. The SkinLesion technology targets this problem by enabling general practitioners in local health centers to perform a skin screening procedure according to the DGS’s Dermatological Telescreening norm, and do so with a much increased efficiency and reduced error rate. It thus greatly facilitates the referral process and ensures dermatologists receive relevant data for triage. On top of that, it offers further support through its automatic melanoma risk assessment tool.”

VRCare

Members: Filipe Freitas Pinto, Tiago Craveiro

VRCare will be the first Virtual Reality Medical Device for the Treatment of Anxiety Disorders that every Mental Health Professional can use with success. 

VRCare provides scientifically tested Virtual Reality Exposure Therapy protocols, combined with advanced biofeedback technology and dynamic 3D environments.